i
Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
-
Jan 2017
-
-
Source: Emerg Infect Dis. 23(1):56-65.
[PDF-956.43 KB]
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:We studied anthrax immune globulin intravenous (AIG-IV) use from a 2009-2010 outbreak of Bacillus anthracis soft tissue infection in injection drug users in Scotland, UK, and we compared findings from 15 AIG-IV recipients with findings from 28 nonrecipients. Death rates did not differ significantly between recipients and nonrecipients (33% vs. 21%). However, whereas only 8 (27%) of 30 patients at low risk for death (admission sequential organ failure assessment score of 0-5) received AIG-IV, 7 (54%) of the 13 patients at high risk for death (sequential organ failure assessment score of 6-11) received treatment. AIG-IV recipients had surgery more often and, among survivors, had longer hospital stays than did nonrecipients. AIG-IV recipients were sicker than nonrecipients. This difference and the small number of higher risk patients confound assessment of AIG-IV effectiveness in this outbreak.
-
Subjects:
-
Source:
-
Pubmed ID:27983504
-
Pubmed Central ID:PMC5176236
-
Document Type:
-
Place as Subject:
-
Location:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
